Mshuham2

Matt Shuham

Matt Shuham is a news writer for TPM. He was previously associate editor of The National Memo and managing editor of the Harvard Political Review. He is available by email at mshuham@talkingpointsmemo.com and on Twitter @mattshuham.

Articles by Matt

A Harley-Davidson factory in Milwaukee backed out of hosting President Donald Trump later this week due to plans for large protests, an anonymous administration official told CNN.

Trump had been scheduled to sign executive orders related to manufacturing at the factory on Thursday.

The official told CNN that while Harley-Davidson was fine with having Trump sign executive orders at its factory, the company was hesitant to host the President amid protests.

Read More →

The CEO of an Australian pharmaceutical company is forcefully denying offering President Donald Trump’s nominee for secretary of Health and Human Services a sweetheart stock deal.

The Wall Street Journal reported Monday that Rep. Tom Price (R-GA) was one of fewer than 20 American investors in Innate Immunotherapeutics, Ltd. to have been offered discounted shares of the company.

But Simon Wilkinson, the company’s CEO and a quoted source for the Journal’s story, wrote to CNN Tuesday that it was “NOT factually correct” to say Price was one of fewer than 20 U.S. investors to have been offered discounted shares.

Read More →

Sen. Sheldon Whitehouse (D-RI) fielded hours of questions Sunday from constituents angry at his supposed cooperation with the Trump administration, even moving to the open air when the middle school auditorium he had booked for a community dinner reached capacity.

Hours after speaking at a rally against President Donald Trump’s immigration executive order, Whitehouse was confronted by many of the same demonstrators at a planned event at Nathan Bishop Middle School in Providence, according to the Providence Journal.

Read More →

An Australian pharmaceutical company says it gave President Donald Trump’s nominee to lead the Department of Health and Human Services an exclusive deal to purchase stock, the Wall Street Journal reported Monday.

That directly contradicts Price's testimony in his confirmation hearings that discounted shares of Innate Immunotherapeutics Ltd. “were available to every single individual that was an investor at the time."

Read More →

LiveWire